Get our Free Drug Patent Expiration Updates

Serving hundreds of leading biopharmaceutical companies globally:

Cantor Fitzgerald
Deloitte
Healthtrust
Daiichi Sankyo
Harvard Business School
Citi
UBS
Baxter
Queensland Health

Generated: December 16, 2018

DrugPatentWatch Database Preview

BALRAPZO Drug Profile

« Back to Dashboard

When do Balrapzo patents expire, and when can generic versions of Balrapzo launch?

Balrapzo is a drug marketed by Eagle Pharms and is included in one NDA. There are six patents protecting this drug.

This drug has fifty-one patent family members in thirty-one countries.

The generic ingredient in BALRAPZO is bendamustine hydrochloride. There are twenty-two drug master file entries for this compound. Four suppliers are listed for this compound. Additional details are available on the bendamustine hydrochloride profile page.

Summary for BALRAPZO
International Patents:51
US Patents:6
Applicants:1
NDAs:1
Suppliers / Packagers: 1
Formulation / Manufacturing:see details
DailyMed Link:BALRAPZO at DailyMed
Drug patent expirations by year for BALRAPZO
Medical Subject Heading (MeSH) Categories for BALRAPZO

US Patents and Regulatory Information for BALRAPZO

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Eagle Pharms BALRAPZO bendamustine hydrochloride SOLUTION;IV (INFUSION) 205580-001 May 15, 2018 RX Yes Yes ➤ Sign Up ➤ Sign Up ➤ Sign Up
Eagle Pharms BALRAPZO bendamustine hydrochloride SOLUTION;IV (INFUSION) 205580-001 May 15, 2018 RX Yes Yes ➤ Sign Up ➤ Sign Up Y ➤ Sign Up
Eagle Pharms BALRAPZO bendamustine hydrochloride SOLUTION;IV (INFUSION) 205580-001 May 15, 2018 RX Yes Yes ➤ Sign Up ➤ Sign Up Y ➤ Sign Up
Eagle Pharms BALRAPZO bendamustine hydrochloride SOLUTION;IV (INFUSION) 205580-001 May 15, 2018 RX Yes Yes ➤ Sign Up ➤ Sign Up Y ➤ Sign Up
Eagle Pharms BALRAPZO bendamustine hydrochloride SOLUTION;IV (INFUSION) 205580-001 May 15, 2018 RX Yes Yes ➤ Sign Up ➤ Sign Up Y ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Cantor Fitzgerald
Deloitte
Healthtrust
Daiichi Sankyo
Harvard Business School
Citi
UBS
Baxter
Queensland Health

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.